Reglan and Tardive Dyskinesia: What Georgia Patients Should Know

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Targeted Risk Recognition

If you or a loved one has taken Reglan for a gastrointestinal condition and now notice uncontrollable facial or body movements, you may be seeing signs of tardive dyskinesia. The medical community has long recognized the importance of monitoring patients on long-term medications, and this awareness now extends to the specific risks associated with metoclopramide. This page outlines the connection between Reglan and tardive dyskinesia, the FDA warnings involved, and what Georgia patients should consider.

Find Out If You Qualify for Compensation →

Understanding Reglan and Its Link to Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information instructs clinicians to use the drug for the shortest duration possible and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the label advises avoiding a total duration of treatment longer than 12 weeks, and if longer-term use is unavoidable, to routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism and Clinical Presentation of Tardive Dyskinesia

Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and/or extremities. The condition can be disfiguring and is often irreversible. The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent abnormal motor control. The label notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The boxed warning emphasizes that if signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central concern. The FDA-mandated boxed warning clearly states the risk, but questions may arise about whether patients and prescribers were adequately informed, especially in cases where Reglan was used off-label or for extended periods. The label explicitly limits use to 12 weeks for gastroesophageal reflux and advises against longer-term use in diabetic gastroparesis unless unavoidable (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, historical prescribing patterns sometimes involved chronic use, which increases cumulative exposure and TD risk. The timeline between exposure and documented harm can vary; TD may develop after months or years of treatment, and symptoms can persist or become permanent even after discontinuation. This latency period complicates the attribution of harm to Reglan, as patients may not immediately connect their movement disorder to past medication use.

Legal Considerations for Georgia Patients: Statute of Limitations

For affected patients in Georgia, attorney-related considerations include the statute of limitations for filing a product liability or personal injury claim. In Georgia, the statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. Given that TD can emerge gradually, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their condition. Patients who developed TD after prolonged Reglan use should consult with an attorney promptly to assess their legal options. Evidence of inadequate warnings or failure to monitor for TD could support a claim, particularly if the prescribing physician did not adhere to the 12-week limit or failed to inform the patient of the risk. The boxed warning and label provide clear documentation of the manufacturer's duty to warn, but individual cases may hinge on whether the warning was effectively communicated to the patient. In summary, Reglan carries a well-documented risk of tardive dyskinesia, with the FDA label providing explicit warnings about duration of use and the need for monitoring. Patients in Georgia who developed TD after Reglan use should be aware of the statute of limitations and seek legal advice to evaluate their claims. The evidence underscores the importance of using Reglan only for approved indications and for the shortest effective duration to minimize TD risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Georgia?

In Georgia, the statute of limitations for personal injury actions is generally two years from the date the injury is discovered or reasonably should have been discovered. For tardive dyskinesia, which can develop gradually, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Reglan caused their condition. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable time frame.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) can cause tardive dyskinesia through its dopamine D2 receptor antagonism in the basal ganglia, leading to supersensitivity of dopamine receptors and abnormal motor control. The risk increases with duration of treatment and total cumulative dosage. The FDA label includes a boxed warning about this risk and advises using Reglan for the shortest duration possible, typically no longer than 12 weeks.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.